(KOD) Kodiak Sciences - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 2.317m USD | Total Return: 922% in 12m
Avg Turnover: 21.4M
Qual. Beats: -1
Qual. Beats: 0
Warnings
Share dilution 17.3% YoY
Altman Z'' -15.00 < 1.0 - financial distress zone
Tailwinds
Leader, Confidence
Kodiak Sciences Inc. (KOD) is a clinical-stage biopharmaceutical company focused on developing therapies for retinal vascular diseases. The company utilizes its proprietary Antibody Biopolymer Conjugate (ABC) platform to design long-acting ophthalmic medicines. Its lead candidate, tarcocimab tedromer (KSI-301), is an anti-VEGF antibody biopolymer currently undergoing Phase 3 clinical evaluations for indications including diabetic retinopathy and wet age-related macular degeneration.
The company’s pipeline also includes KSI-501 and KSI-101, which are bispecific candidates targeting both IL-6 and VEGF to address inflammation and retinal fluid. Biopharmaceutical firms in the ophthalmology sector typically face high R&D costs and rigorous regulatory hurdles, as success depends on demonstrating superior durability and safety compared to existing blockbuster anti-VEGF injections. Investors may find additional data points on ValueRay useful for evaluating these clinical milestones.
Headquartered in Palo Alto, California, Kodiak Sciences transitioned from Oligasis, LLC in 2015. The business model relies on advancing its ABC platform candidates through the clinical trial continuum toward potential commercialization or strategic partnerships.
- Tarcocimab clinical trial data readouts determine long-term commercial viability and valuation
- FDA approval timelines for lead candidate KSI-301 dictate market entry potential
- Research and development expenses for bispecific antibodies drive cash burn rates
- Competitive pressure from established anti-VEGF therapies impacts future market share
- Success of KSI-501 bispecific platform influences pipeline diversification and investor confidence
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.47 > 0.02 and ΔFCF/TA -11.45 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.48 > 3% & CFO -146.9m > Net Income -230.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (61.9m) vs 12m ago 17.28% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 8.95%; Δ -8.95% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.41 (Total Current Assets 175.3m - Total Current Liabilities 49.6m) / Total Assets 306.0m |
| B: -5.28 (Retained Earnings -1.62b / Total Assets 306.0m) |
| C: -0.76 (EBIT TTM -230.7m / Avg Total Assets 302.0m) |
| D: -8.34 (Book Value of Equity -1.62b / Total Liabilities 193.9m) |
| Altman-Z'' = -28.42 = D |
As of May 24, 2026, the stock is trading at USD 37.41 with a total of 450,338 shares traded.
Over the past week, the price has changed by -2.13%,
over one month by -19.83%,
over three months by +35.79% and
over the past year by +922.00%.
Kodiak Sciences has received a consensus analysts rating of 2.83. Therefore, it is recommended to hold KOD.
- StrongBuy: 1
- Buy: 0
- Hold: 2
- Sell: 3
- StrongSell: 0
| Analysts Target Price | 62.7 | 67.5% |
Revenue TTM = 0.0 USD
EBIT TTM = -230.7m USD
EBITDA TTM = -204.7m USD
Long Term Debt = 44.3m USD (estimated: total debt 56.0m - short term 11.7m)
Short Term Debt = 11.7m USD (from shortTermDebt, last quarter)
Debt = 56.0m USD (from shortLongTermDebtTotal, last quarter) (leases 56.0m already included)
Net Debt = -112.1m USD (calculated: Debt 56.0m - CCE 168.1m)
Enterprise Value = 2.20b USD (2.32b + Debt 56.0m - CCE 168.1m)
Interest Coverage Ratio = unknown (Ebit TTM -230.7m / Interest Expense TTM 0.0)
EV/FCF = -15.23x (Enterprise Value 2.20b / FCF TTM -144.7m)
FCF Yield = -6.57% (FCF TTM -144.7m / Enterprise Value 2.20b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM -388k) / Revenue TTM)
Tobins Q-Ratio = 7.20 (Enterprise Value 2.20b / Total Assets 306.0m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 56.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -182.2m (EBIT -230.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.88 (Total Current Assets 175.3m / Total Current Liabilities 60.9m)
Debt / Equity = 0.50 (Debt 56.0m / totalStockholderEquity, last quarter 112.1m)
Debt / EBITDA = 0.55 (negative EBITDA) (Net Debt -112.1m / EBITDA -204.7m)
Debt / FCF = 0.77 (negative FCF - burning cash) (Net Debt -112.1m / FCF TTM -144.7m)
Total Stockholder Equity = 90.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -76.39% (Net Income -230.7m / Total Assets 306.0m)
RoE = -13.51% (Net Income TTM -230.7m / Total Stockholder Equity 1.71b)
RoCE = -13.17% (EBIT -230.7m / Capital Employed (Equity 1.71b + L.T.Debt 44.3m))
RoIC = -182.2% (out of range, set to none) (NOPAT -182.2m / Invested Capital 100.0m)
WACC = 13.29% (E(2.32b)/V(2.37b) * Re(13.61%) + D(56.0m)/V(2.37b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 13.61% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 100.00 | Cagr: 7.58%
[DCF] Fair Price = unknown (Cash Flow -144.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -2.48 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.96 | Chg30d=+6.96% | Revisions=+20% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-0.93 | Chg30d=+7.95% | Revisions=+20% | Analysts=6
EPS current Year (2026-12-31): EPS=-3.74 | Chg30d=+7.78% | Revisions=+20% | GrowthEPS=+13.4% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.12 | Chg30d=+8.76% | Revisions=+20% | GrowthEPS=+16.7% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +20%